Phase III placebo-controlled, double-blind, randomized trial of pegfilgrastim to reduce the risk of febrile neutropenia in breast cancer patients receiving docetaxel/cyclophosphamide chemotherapy

Supportive Care in Cancer

Volumn 23, Issue 4, 2015, Pages 1137-1143

  Kosaka, Yoshimasa ^a   Rai, Yoshiaki ^b   Masuda, Norikazu ^c   Takano, Toshimi ^d   Saeki, Toshiaki ^e   Nakamura, Seigo ^f   Shimazaki, Ryutaro ^g   Ito, Yoshinori ^h   Tokuda, Yutaka ⁱ   Tamura, Kazuo ^j  

^a KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b SAGARA HOSPITAL   (Japan)

^c OSAKA NATIONAL HOSPITAL   (Japan)

^d TORANOMON HOSPITAL   (Japan)

^e SAITAMA MEDICAL UNIVERSITY INTERNATIONAL MEDICAL CENTER   (Japan)

^f SHOWA UNIVERSITY HOSPITAL   (Japan)

^g KYOWA HAKKO KOGYO CO LTD   (Japan)

^h CANCER INSTITUTE HOSPITAL   (Japan)

ⁱ TOKAI UNIVERSITY HOSPITAL   (Japan)

^j FUKUOKA UNIVERSITY HOSPITAL   (Japan)

more..

Author keywords

Adjuvant therapy; Breast cancer; Docetaxel cyclophosphamide therapy; Febrile neutropenia; Granulocyte colony stimulating factor (G CSF); Pegfilgrastim

Indexed keywords

ANTIBIOTIC AGENT; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; PEGFILGRASTIM; PLACEBO; ANTINEOPLASTIC AGENT; GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT PROTEIN; TAXOID;

ADULT; AGED; ARTICLE; BACKACHE; BONE PAIN; BREAST CANCER; BREAST CARCINOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER INCIDENCE; CANCER RISK; CANCER STAGING; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEBRILE NEUTROPENIA; FEMALE; HOSPITALIZATION; HUMAN; JAPANESE (PEOPLE); MAJOR CLINICAL STUDY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; ADJUVANT CHEMOTHERAPY; BREAST NEOPLASMS; CHEMOTHERAPY-INDUCED FEBRILE NEUTROPENIA; CLINICAL TRIAL; MIDDLE AGED; PROGNOSIS; RISK; SURVIVAL RATE; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CHEMOTHERAPY-INDUCED FEBRILE NEUTROPENIA; CYCLOPHOSPHAMIDE; DOUBLE-BLIND METHOD; DOXORUBICIN; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; MIDDLE AGED; PROGNOSIS; RECOMBINANT PROTEINS; RISK; SURVIVAL RATE; TAXOIDS; TREATMENT OUTCOME;

EID: 84942105206     PISSN: 09414355     EISSN: 14337339     Source Type: Journal    
DOI: 10.1007/s00520-014-2597-1     Document Type: Article

References (21)

1. Blackwell S, Crawford J (1994) Filgrastim (r-metHuG-CSF) in the chemotherapy setting. In: Morstyn G, Dexter TM (eds) Filgrastim (r-metHuG-CSF) in Clinical Practice. Marcel Dekker, Inc., New York, pp 103–116
2. Bosly A, Bron D, van Hoof A, de Bock R, Berneman Z, Ferrant A, Kaufman L, Dauwe M, Verhoef G (2008) Achievement of optimal average relative dose intensity and correlation with survival in diffuse large B-cell lymphoma patients treated with CHOP. Ann Hematol 87:277–283. doi:10.1007/s00277-007-0399-y
3. Lyman GH, Dale DC, Friedberg J, Crawford J, Fisher RI (2004) Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin’s lymphoma: a nationwide study. J Clin Oncol 22:4302–4311. doi:10.1200/JCO.2004.03.213
4. Smith TJ, Khatcheressian J, Lyman GH, Ozer H, Armitage JO, Balducci L, Bennett CL, Cantor SB, Crawford J, Cross SJ, Demetri G, Desch CE, Pizzo PA, Schiffer CA, Schwartzberg L, Somerfield MR, Somlo G, Wade JC, Wade JL, Winn RJ, Wozniak AJ, Wolff AC (2006) 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 24:3187–3205. doi:10.1200/JCO.2006.06.4451
5. National Comprehensive Cancer Network (2014) Clinical practice guidelines in oncology: myeloid growth factors, version 1. National Comprehensive Cancer Network. http://www.nccn.org/professionals/physician_gls/pdf/myeloid_growth.pdf. Accessed 6 June 2014
6. Aapro MS, Bohlius J, Cameron DA, Dal Lago L, Donnelly JP, Kearney N, Lyman GH, Pettengell R, Tjan-Heijnen VC, Walewski J, Weber DC, Zielinski C, European Organisation for Research and Treatment of Cancer (2011) 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer 47:8–32. doi:10.1016/j.ejca.2010.10.013
7. Japan Society of Clinical Oncology Clinical Practice Guideline [homepage on the Internet]. Japan Society of Clinical Oncology. G-CSF supportive treatment. http://www.jsco-cpg.jp/item/30/index.html. Accessed 6 June 2014
8. Vogel CL, Wojtukiewicz MZ, Carroll RR, Tjulandin SA, Barajas-Figueroa LJ, Wiens BL, Neumann TA, Schwartzberg LS (2005) First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study. J Clin Oncol 23:1178–1184. doi:10.1200/JCO.2005.09.102
9. Masuda N, Nakamura S, Ito Y, Tokuda Y, Tamura K (2011) A multicenter randomized phase II study of KRN125 (pegfilgrastim) to determine the optimal dosage in Japanese breast cancer patients receiving TAC treatment. Eur J Cancer 47:S380
10. Jones SE, Savin MA, Holmes FA, O’Shaughnessy JA, Blum JL, Vukelja S, McIntyre KJ, Pippen JE, Bordelon JH, Kirby R, Sandbach J, Hyman WJ, Khandelwal P, Negron AG, Richards DA, Anthony SP, Mennel RG, Boehm KA, Meyer WG, Asmar L (2006) Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. J Clin Oncol 24:5381–5387. doi:10.1200/JCO.2006.06.5391
11. Soong D, Haj R, Leung MG, Myers R, Higgins B, Myers J, Rajagopal S (2009) High rate of febrile neutropenia in patients with operable breast cancer receiving docetaxel and cyclophosphamide. J Clin Oncol 27:e101–e102. doi:10.1200/JCO.2009.23.0508
12. Vandenberg T, Younus J, Al-Khayyat S (2010) Febrile neutropenia rates with adjuvant docetaxel and cyclophosphamide chemotherapy in early breast cancer: discrepancy between published reports and community practice—a retrospective analysis. Curr Oncol 17:2–3
13. Takabatake D, Taira N, Hara F, Sien T, Kiyoto S, Takashima S, Aogi K, Ohsumi S, Doihara H, Takashima S (2009) Feasibility study of docetaxel with cyclophosphamide as adjuvant chemotherapy for Japanese breast cancer patients. Jpn J Clin Oncol 39:478–483. doi:10.1093/jjco/hyp050
14. Kawabata H, Iwatani T, Makuuchi R, Miura D, Suzuki N, Nakazawa H (2010) Safety and tolerability of docetaxel with cyclophosphamide for early breast cancer. Gan To Kagaku Ryoho 37:835–839
15. Trent JC, Valero V, Booser DJ, Esparza-Guerra LT, Ibrahim N, Rahman Z, Vernillet L, Patel S, David CL, Murray JL, Cristofanilli M, Hortobagyi GN (2003) A phase I study of docetaxel plus cyclophosphamide in solid tumors followed by a phase II study as first-line therapy in metastatic breast cancer. Clin Cancer Res 9:2426–2434
16. Chan A, Fu WH, Shih V, Coyuco JC, Tan SH, Ng R (2011) Impact of colony-stimulating factors to reduce febrile neutropenic events in breast cancer patients receiving docetaxel plus cyclophosphamide chemotherapy. Support Care Cancer 19:497–504. doi:10.1007/s00520-010-0843-8
17. Martín M, Lluch A, Seguí MA, Ruiz A, Ramos M, Adrover E, Rodríguez-Lescure A, Grosse R, Calvo L, Fernandez-Chacón C, Roset M, Antón A, Isla D, del Prado PM, Iglesias L, Zaluski J, Arcusa A, López-Vega JM, Muñoz M, Mel JR (2006) Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte-colony stimulating factor to the TAC regimen. Ann Oncol 17:1205–1212. doi:10.1093/annonc/mdl135
18. Younis T, Rayson D, Thompson K (2012) Primary G-CSF prophylaxis for adjuvant TC or FEC-D chemotherapy outside of clinical trial settings: a systematic review and meta-analysis. Support Care Cancer 20:2523–2530. doi:10.1007/s00520-011-1375-6
19. Masaoka T (2004) Evidence-based recommendations for antimicrobial use in febrile neutropenia in Japan: executive summary. Clin Infect Dis 39:S49–S52. doi:10.1086/383054
20. Gandara DR, Kawaguchi T, Crowley J, Moon J, Furuse K, Kawahara M, Teramukai S, Ohe Y, Kubota K, Williamson SK, Gautschi O, Lenz HJ, McLeod HL, Lara PN Jr, Coltman CA Jr, Fukuoka M, Saijo N, Fukushima M, Mack PC (2009) Japanese-US common-arm analysis of paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a model for assessing population-related pharmacogenomics. J Clin Oncol 27:3540–3546. doi:10.1200/JCO.2008.20.8793
21. Han HS, Reis IM, Zhao W, Kuroi K, Toi M, Suzuki E, Syme R, Chow L, Yip AY, Glück S (2011) Racial differences in acute toxicities of neoadjuvant or adjuvant chemotherapy in patients with early-stage breast cancer. Eur J Cancer 47:2537–2545. doi:10.1016/j.ejca.2011.06.027